Levee Medical

Read the full announcement: prnewswire.com/news-releases/… #LeveeMedical #Voro #ClinicalTrials #Urology #ProstateCancer #MedicalDevice #MedTech #HealthcareInnovation

evaluating continence recovery following prostate cancer surgery. We extend our sincere thanks to everyone who contributed to reaching this milestone and look forward to sharing future updates as the ARID II study progresses.

We are proud to announce the completion of patient enrollment in the ARID II pivotal trial evaluating the investigational Voro Urologic Scaffold. This milestone reflects the dedication of the study participants and clinical teams across leading academic and community urology

conversation around the future of continence recovery after prostatectomy. #AUA2026 #Urology #ProstateCancer #MedicalInnovation #ClinicalResearch #LeveeMedical #Prostatectomy #MensHealth

vision behind Voro and the impact we hope to make for men recovering after prostate cancer surgery. 🎥 youtube.com/watch?v=sjEbvF… We look forward to connecting with the urology community at AUA 2026 and continuing the

As we count down to AUA 2026, we’re proud to share this powerful look at the mission driving Levee Medical forward — improving recovery and quality of life for men undergoing prostate cancer surgery. The investigational Voro Urologic Scaffold was designed to address

Big milestone! Congrats to @HopkinsMedicine & Dr. Arun Rai for enrolling their 1st patient in the ARID II IDE pivotal trial of the Voro® Urologic Scaffold. One step closer to improving outcomes after prostate surgery. #ARIDII #PivotalTrial #ProstateSurgery #PatientOutcomes

post-operative urinary incontinence and the quality of life impact that often goes underrecognized.” — Gautam Jayram, M.D., Urology Associates of Nashville One step closer to improving outcomes after prostate surgery. #ARIDII #PivotalTrial #ProstateSurgery #PatientOutcomes

Congrats to Urology Associates of Nashville & Dr. Gautam Jayram for enrolling their 1st patient in the ARID II IDE pivotal trial – our 17th site to randomize! “Excited to be the first in Nashville to enroll patients in the ARID II clinical trial, supporting research focused on

Big milestone! Congrats to Tampa General Hospital and Dr. Trushar Patel for enrolling their 1st patient in the ARID II IDE pivotal trial of the Voro® Urologic Scaffold. One step closer to improving outcomes after prostate surgery. #ARIDII #PivotalTrial #ProstateSurgery

Missed the first two? Video 1: youtube.com/watch?v=Id0Bbm… Video 2: youtu.be/Vc5AfTsLFqc?si… #LeveeMedical #HiddenCost #MensHealth #Urology #MedTech

The true cost of post-prostatectomy incontinence is rarely visible. In Video 3 of our Hidden Cost series, patients share the realities that extend far beyond the clinical diagnosis. Watch now: youtu.be/ZZtOZJ_M2zA?si…

Congrats to Academic Urology & Drs. Justin Campagna and Jeffrey Stern for enrolling their 1st patient in the ARID II IDE pivotal trial – our 16th site to randomize! One step closer to improving outcomes after prostate surgery. #ARIDII #PivotalTrial #ProstateSurgery

Big milestone! Congrats to the University of Rochester & Dr. Thomas Frye for enrolling their 1st patient in the ARID II IDE pivotal trial of the Voro® Urologic Scaffold. One step closer to improving outcomes after prostate surgery. #ARIDII #PivotalTrial #ProstateSurgery

Congrats to UChicago Medicine & Dr. Abhinav Sidana for enrolling their 1st patient in the ARID II IDE pivotal trial – our 15th site to randomize! One step closer to improving outcomes after prostate surgery. #ARIDII #PivotalTrial #ProstateSurgery #PatientOutcomes

#LeveeMedical #MedTech #ClinicalTrials #Urology #MedicalInnovation

With growing clinical adoption and strong investor support, we are accelerating execution with a clear focus: improving recovery and outcomes for men undergoing prostate cancer surgery. Learn more about our progress and what’s ahead. prnewswire.com/news-releases/…

We are excited to announce that we have closed an oversubscribed $12M+ financing round ahead of schedule, strengthening our position as we advance toward PMA submission and continue enrolling leading surgeons in the ARID II pivotal trial of the Voro® Urologic Scaffold.